PROCEPT BioRobotics (PRCT) vs Tandem Diabetes Care (TNDM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PROCEPT BioRobotics (PRCT) has outperformed Tandem Diabetes Care (TNDM) over the past year, losing 17.3% versus a loss of 18.0%. Over five years, PRCT leads with a -30.6% price change compared with -86.5% for TNDM. PROCEPT BioRobotics is the larger company by market cap ($1.42 billion vs $1.22 billion), about 1.2 times the size.
Tandem Diabetes Care converts more of its revenue into profit, with a net margin of -20.2% versus -31.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRCT | TNDM |
|---|---|---|
| Share price | $24.70 | $17.46 |
| Market cap | $1.42B | $1.22B |
| 1-day change | -4.08% | +3.93% |
| YTD return | -21.49% | -20.56% |
| 1-year return | -17.28% | -17.95% |
| 5-year return | -30.64% | -86.53% |
| Forward P/E | — | 195.48 |
| EPS (TTM) | $-2.02 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $308.05M | $1.01B |
| Revenue growth (YoY) | +37.22% | +7.93% |
| Net income (latest FY) | $-95.57M | $-204.71M |
| Gross margin | 63.70% | 53.81% |
| Operating margin | -33.71% | -18.45% |
| Net margin | -31.02% | -20.17% |
| 52-week high | $38.11 | $29.65 |
| 52-week low | $16.67 | $12.26 |
| Distance from 52-week high | -35.19% | -41.11% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -7.89% | +55.21% |
| Average volume | 1.31M | 2.26M |
| Shares outstanding | 57.54M | 69.79M |
| Employees | 888 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Tandem Diabetes Care is more profitable, keeping -20.2 cents of every revenue dollar as net income versus -31.0 cents for PROCEPT BioRobotics.
- PROCEPT BioRobotics grew revenue faster in its latest fiscal year (+37.22% vs +7.93%).
About PROCEPT BioRobotics
PRCT stock →PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Health Care · Medical/Dental Instruments · 888 employees
About Tandem Diabetes Care
TNDM stock →Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally.
Health Care · Medical/Dental Instruments · 2,500 employees
PRCT vs TNDM FAQ
Which is bigger, PROCEPT BioRobotics or Tandem Diabetes Care?
PROCEPT BioRobotics (PRCT) is larger, with a market capitalization of $1.42B compared with $1.22B for Tandem Diabetes Care (TNDM).
Which stock has performed better over the past year, PRCT or TNDM?
PRCT returned -17.28% over the past 12 months, compared with -17.95% for TNDM (price return, excluding dividends). Past performance does not predict future results.
Are PROCEPT BioRobotics and Tandem Diabetes Care in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.